Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments ...

Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural ...

A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant ...

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition rate of ~90% observed in GP2D human colorectal cancer cells; ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted ...

A 56-year-old man presented for 3 weeks of intermittent blurred vision and photophobia.His medical history included type 2 diabetes, hypertension, hyperlipidemia, chronic obstructive pulmonary disease ...

proliferation, and migration. 3 Initial investigation of HIF-2α inhibitors, such as MK-3795 (previously known as PT2385), in preclinical studies demonstrated promising results. For example, a first-in ...

Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China ...

In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape drug-induced quiescence through a nongenetic manner of adaptation and resume slow proliferation. Here, we ...